Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Third Intergroup Rhabdomyosarcoma Study

W Crist1, E A Gehan, A H Ragab

  • 1Childrens Cancer Group, Arcadia CA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Leukemia & lymphoma·2026
Same author

The effect of branded versus standardized e-cigarette packaging and device designs: an experimental study of youth interest in vaping products.

Public health·2024
Same author

Re: Some weighing of publication rates should be used to more fairly reflect the productivity of trainees. Re: re: Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2021
Same author

Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2020
Same author

Prevalence and pattern of energy drink intake among Australian adolescents.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
Same author

Setting up and maximising the usage of an Urgent Dental Care Centre in Blackpool. Sharing our experiences.

The British journal of oral & maxillofacial surgery·2020
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

The Third Intergroup Rhabdomyosarcoma Study (IRS-III) improved rhabdomyosarcoma treatment outcomes in children by intensifying risk-based therapies. This strategy significantly enhanced overall survival, particularly for patients with gross residual tumor after biopsy.

Area of Science:

  • Pediatric Oncology
  • Clinical Trials
  • Rhabdomyosarcoma Research

Background:

  • Rhabdomyosarcoma is a common childhood cancer requiring effective treatment strategies.
  • Previous studies (IRS-II) established baseline treatment protocols.
  • The Third Intergroup Rhabdomyosarcoma Study (IRS-III) aimed to build upon prior findings.

Purpose of the Study:

  • To improve treatment outcomes for pediatric rhabdomyosarcoma patients.
  • To compare risk-based treatment protocols involving surgery, chemotherapy, and irradiation.
  • To evaluate the efficacy of intensified therapeutic regimens.

Main Methods:

  • 1,062 previously untreated patients were randomized based on clinical group, histology, and tumor site.
  • Treatment protocols compared different combinations of surgery, multiagent chemotherapy (e.g., vincristine, dactinomycin, cyclophosphamide, doxorubicin), and irradiation.

Related Experiment Videos

  • Progression-free survival (PFS) and overall survival (S) were key endpoints.

    • Main Results:

    • Overall outcome in IRS-III was significantly better than in IRS-II (5-year PFS: 65% vs. 55%).
    • Patients with favorable-histology group I tumors showed similar PFS with or without cyclophosphamide.
    • Intensified regimens in IRS-III significantly improved PFS for group III tumors compared to IRS-II (62% vs. 52%).
    • Patients with metastatic disease (group IV) did not show significant benefit from intensified therapies.

    Conclusions:

    • Risk-based intensification of therapy in IRS-III significantly improved overall treatment outcomes for pediatric rhabdomyosarcoma.
    • The greatest benefit was observed in patients with gross residual tumor (group III).
    • Therapy could be reduced for certain patient subsets without compromising survival outcomes.